Company intelligence / Profile preview

Avelo

Schlieren, Zurich, Switzerlandaveloair.com ↗

Ownership: Private
Development stage: Other

Overview

Avelo has developed a non-invasive breath sampling device ("AveloCollect") for rapid and accurate diagnosis of lower respiratory tract infections. The device collects pathogens directly from exhaled breath using a proprietary filter. In partnership with VIVOLTA and BLINK, the collected samples are analyzed using digital PCR to identify multiple pathogens simultaneously. The technology aims to improve diagnostic accuracy over current methods such as swabs or invasive procedures and is in clinical validation phases with grant support for further development.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic
Industry: Molecular Diagnostics

Partnerships

VIVOLTA (manufacturing partner for electrospun filters)BLINK (digital PCR molecular diagnostics partner)

Beyond the preview

Go deeper on Avelo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avelo.

Explore the full profile